Drugs / SB-AS15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00086866 | May 2004 → Jan 2007 | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-AS15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00086866 ↗ |
| Route | Intramuscular | “Patients receive immunization comprising D1/3-MAGE-3-His fusion protein SB-AS15 adjuvant IM once weekly” NCT00086866 ↗ |